Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...

Novartis posts solid Q2 results, raises 2025 earnings outlook, launches $10 billion share buyback, and announces CFO ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the second quarter of 2025 and upped annual ...

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

Pluvicto is a targeted radioligand therapy, meaning it uses radioactive atoms to deliver radiation to targeted cells, fighting cancer while limiting damage to the surrounding tissues.

EAST HANOVER, N.J., March 23, 2022 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly ...

“Pluvicto is a radiation treatment, but not with a beam, it’s given with an IV into the body, and it’s a very sophisticated concept,” said Dr. Gary Kirsh, a urologist at The Urology Group.

The Food and Drug Administration said last week the availability of Pluvicto is limited as manufacturer Novartis AG struggles to meet demand. The drugmaker said the shortage stems from ...

Pluvicto, a drug to treat metastatic castration-resistant prostate cancer, also known as mCRPC, is in such short supply that its maker, Novartis, said it cannot allow further supply to new ...